Estimation of cost savings between 2011 and 2014 attributed to infliximab biosimilar in the South Korean healthcare market: real-world evidence using a nationwide database-Reference-Cited by-同舟云学术

Estimation of cost savings between 2011 and 2014 attributed to infliximab biosimilar in the South Korean healthcare market: real-world evidence using a nationwide database

Published:2018-04-17 Issue:6 Volume:21 Page:1227-1236
ISSN:1756-1841
Container-title:International Journal of Rheumatic Diseases
language:en
Short-container-title:Int J Rheum Dis

Author:

Kim Jiyoun¹,Ha Dongmun¹^ORCID,Song Inmyung¹,Park Haesun¹,Lee Sang-Won¹,Lee Eui-Kyung¹,Shin Ju-Young¹

Affiliation:

1. School of Pharmacy; Sungkyunkwan University; Suwon Korea

Publisher

Wiley

Subject

Rheumatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1756-185X.13295/fullpdf

Reference25 articles.

1. Inequities in access to biologic and synthetic DMARDs across 46 European countries;Putrik;Ann Rheum Dis,2014

2. The burden of rheumatoid arthritis and access to treatment: health burden and costs;Lundkvist;Eur J Health Econom,2008

3. Suboptimal management of rheumatoid arthritis in the Middle East and Africa: could the EULAR recommendations be the start of a solution?;El Zorkany;Clin Rheumatol,2013

4. Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe;Rencz;World J Gastroenterol,2015

5. The challenge of biosimilars;Mellstedt;Ann Oncol,2008

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Industry perspective on regulatory authority (RA) quality reviews of biosimilar applications – an evaluation of RA guidance and expectations for chemical, manufacturing, and controls information through in-depth query analysis;Expert Opinion on Biological Therapy;2024-07-02

2. Evaluation of the drug utilization of biosimilar medicinal products containing monoclonal antibodies: A systematic review;Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector;2022-02-23

3. Physicochemical stability of PF-05280014 (trastuzumab-qyyp; Trazimera^TM), a trastuzumab biosimilar, under extended in-use conditions;Journal of Oncology Pharmacy Practice;2022-01-24

4. Availability, affordability and drug utilization of biosimilar medicinal products, containing monoclonal antibodies in Bulgaria;Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector;2021-05-20

5. Uptake of Biosimilars and Its Economic Implication for the Treatment of Patients with Rheumatoid Arthritis in Korea;Journal of Korean Medical Science;2021